SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Bo Feldt-Rasmussen; Rikke Borg; Jan Carstens; Ditte Hansen; Mads Hornum; Morten Lindhardt; Frank Holden Mose; Birgitte Bang Pedersen; Johan Vestergaard Poulsen; Kristine Dyhr Schandorff; Charlotte Strandhave

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Translated title of the contribution: SGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure

Bo Feldt-Rasmussen, Rikke Borg, Jan Carstens, Ditte Hansen, Mads Hornum, Morten Lindhardt, Frank Holden Mose, Birgitte Bang Pedersen, Johan Vestergaard Poulsen, Kristine Dyhr Schandorff, Charlotte Strandhave

Research output: Contribution to journal › Review › Research › peer-review

14 Downloads (Pure)

Abstract

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

Translated title of the contribution	SGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure
Original language	Danish
Article number	V11210887
Journal	Ugeskrift for Laeger
Volume	184
Issue number	16
Number of pages	8
ISSN	0041-5782
Publication status	Published - 18 Apr 2022

Access to Document

FulltextFinal published version, 444 KBLicence: CC BY-NC-ND

https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf

Cite this

Feldt-Rasmussen, B., Borg, R., Carstens, J., Hansen, D., Hornum, M., Lindhardt, M., Mose, F. H., Pedersen, B. B., Poulsen, J. V., Schandorff, K. D., & Strandhave, C. (2022). SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. Ugeskrift for Laeger, 184(16), [V11210887]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. / Feldt-Rasmussen, Bo ; Borg, Rikke; Carstens, Jan; Hansen, Ditte ; Hornum, Mads ; Lindhardt, Morten; Mose, Frank Holden; Pedersen, Birgitte Bang; Poulsen, Johan Vestergaard; Schandorff, Kristine Dyhr; Strandhave, Charlotte.

In: Ugeskrift for Laeger, Vol. 184, No. 16, V11210887, 18.04.2022.

Research output: Contribution to journal › Review › Research › peer-review

Feldt-Rasmussen, B , Borg, R, Carstens, J, Hansen, D , Hornum, M , Lindhardt, M, Mose, FH, Pedersen, BB, Poulsen, JV, Schandorff, KD & Strandhave, C 2022, 'SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt', Ugeskrift for Laeger, vol. 184, no. 16, V11210887. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf>

@article{b6132084a27349649739d74577d21168,

title = "SGLT2-h{\ae}mning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt",

abstract = "This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.",

keywords = "Diabetes Mellitus, Electroconvulsive Therapy/adverse effects, Female, Heart Failure/drug therapy, Humans, Male, Renal Insufficiency, Chronic/complications, Sodium-Glucose Transporter 2",

author = "Bo Feldt-Rasmussen and Rikke Borg and Jan Carstens and Ditte Hansen and Mads Hornum and Morten Lindhardt and Mose, {Frank Holden} and Pedersen, {Birgitte Bang} and Poulsen, {Johan Vestergaard} and Schandorff, {Kristine Dyhr} and Charlotte Strandhave",

year = "2022",

month = apr,

day = "18",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "16",

}

TY - JOUR

T1 - SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

AU - Feldt-Rasmussen, Bo

AU - Borg, Rikke

AU - Carstens, Jan

AU - Hansen, Ditte

AU - Hornum, Mads

AU - Lindhardt, Morten

AU - Mose, Frank Holden

AU - Pedersen, Birgitte Bang

AU - Poulsen, Johan Vestergaard

AU - Schandorff, Kristine Dyhr

AU - Strandhave, Charlotte

PY - 2022/4/18

Y1 - 2022/4/18

N2 - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

AB - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

KW - Diabetes Mellitus

KW - Electroconvulsive Therapy/adverse effects

KW - Female

KW - Heart Failure/drug therapy

KW - Humans

KW - Male

KW - Renal Insufficiency, Chronic/complications

KW - Sodium-Glucose Transporter 2

M3 - Review

C2 - 35485777

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 16

M1 - V11210887

ER -